PHARMARON, INC
LOUISVILLE, KENTUCKY 402021249
Top Industries (NAICS)
| NAICS Code | Obligations | Awards |
|---|---|---|
| 541380 | $828K | 29 |
| 541990 | $-19,045 | 4 |
| 621511 | $-142,250 | 1 |
Contract Awards
22 awards found
PK STUDY IN MICE
TO ADMINISTRATIVELY DE-OBLIGATE UNEXPENDED AND EXPIRING FISCAL YEAR 2020 FUNDING IN ACCORDANCE WITH 31 U.S.C. SECTION 1552 (A), IN PREPARATION FOR SEPTEMBER 30, 2025, CLOSING OF THE PERIOD OF AVAILABILITY OF THESE FISCAL YEAR FUNDS.
PHARMARON, INC.:1208250 [24-007232]
PHARMACOKINETIC STUDIES OF TWO COMPOUNDS IN NON-NAIVE CYNOMOLGUS MONKEYS, USING BOTH ORAL AND INTRAVENOUS ROUTES OF ADMINISTRATION, WITH BIOANALYSES IN PLASMA CONDUCTED IN TRIPLICATE. PHARMARON, INC.:1208250 [24-007191]
TESTING OF COMPOUNDS IN CARDIAC ION CHANNEL ASSAYS
PHARMACOKINETICS EXPERIMENTS, N=40, 2 ARM, RODENT
EVALUATING ADME OF COMPOUNDS FROM DYSTONIA PROJECT
EVALUATING PHARMACOKINETICS OF COMPOUNDS FROM DYSTONIA IN MICE, DOGS, RATS
MAXIMALLY TOLERATED DOSE (MTD) AND 14-DAY DOSE RANGE-FINDING (DRF) TOXICITY STUDY IN MALE AND FEMALE RATS
PHARMACOKINETIC STUDY TAMOXIFEN AND NEUROTINIB
PHARMACOKINETICS ASSESSMENT OF EIGHT (8) NOVEL COMPOUNDS IN MICE AND RATS
PHARMACOKINETIC STUDY (PK) AT PHARMARON USING A NOVEL POLYMERIC FORMULATION DEVELOPED BY THE UNIVERSITY OF KANSAS ON 1 COMPOUND (NCGC0084604) IN MALE C57BL/6J MICE USING COMPOUND-IN-CHOW DOSING AT 3, 10, AND 30 MG/KG.
PHARMACOKINETIC STUDY (PK) INVOLVING NCGC00413972 IN THREE DIFFERENT FORMS: (1) ABSORBED IN A POLYMER IN CHOW, (2) SOLID IN CHOW (BOTH @ 3,10,30MG/KG) AND (3) PK STUDY ON NCGC00413972 (PO AND IP 10MG/KG AND PO AND IP 30MG/KG)
PK MOUSE IV, PO AND IP STUDY AT 3 CONCENTRATIONS
6-DAY TOLERABILITY/PK STUDY IN THE GOLDEN SYRIAN HAMSTER EFFICACY MODEL OF SARS-COV-2 INFECTION. POP IS FOUR WEEKS FROM RECEIPT OF TEST ARTICLE COMPOUNDS.
THE PURPOSE OF THIS MODIFICATION IS TO DE-OBLIGATE EXPIRING FUNDS IN ACCORDANCE WITH FAR 52.232-20, LIMITATION OF COST.
TESTING OF COMPOUNDS FOR BLOCK OF CARDIAC ION CHANNELS
DETERMINE IN VIVO PLASMA, BRAIN, AND LIVER EXPOSURES IN MICE AFTER SINGLE IV OR PO ADMINISTRATION FOR 5 COMPOUNDS
BIOANALYSIS TESTING SERVICES DELIVERY ORDER # 2018-003 IN VIVO PK SERVICES
EVALUATING NNMT INHIBITORS IN METABOLIC DISORDERS
PHARMACOKINETICS ASSESSMENT TESTING SERVICES OF COMPOUNDS IN MICE AND RATS
TESTING OF COMPOUNDS IN RAT PHARMACOKINETIC STUDIES
Business Details
- UEI
- L8NQAFSTPSY9
- CAGE Code
- 4LFM9
- Address
- 201 E JEFFERSON ST STE 304
LOUISVILLE, KY 402021249 - Congressional District
- KY-03
- Phone
- 5626869786
Parent Company
PHARMARON (BEIJING) NEW MEDICINE TECHNOLOGY CO. LTD
Data Source
This profile is based on federal contract award data from USAspending.gov.
View on USAspending.gov